Drug Search Results

Troxacitabine

Alternative Names: troxacitabine
Latest Update: 2024-09-16
Latest Update Note: News Article

Product Description

Mechanisms of Action: Nucleoside Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Troxacitabine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
BCH-4556-214	P2	Completed	Chronic Myeloid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2002-03-27	55%
SPD758-216	P2	Terminated	Acute Myeloid Leukemia	None

Recent News Events

Date	Type	Title
09/16/2024	News Article	Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO
09/12/2024	News Article	Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16
07/18/2024	News Article	Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September
06/27/2024	News Article	Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions